- Home
- OIA vs CDXS Comparison
OIA vs CDXS Comparison
Compare OIA & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OIA | CDXS |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Major Chemicals |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.4M | 256.3M |
| IPO Year | 1994 | 2008 |
Fundamental Metrics
Financial Performance| Metric | OIA | CDXS |
|---|---|---|
| Price | $5.76 | $1.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 98.7K | ★ 814.2K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | N/A | $7.73 |
| Revenue Next Year | N/A | $14.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $5.82 | $0.96 |
| 52 Week High | $6.40 | $2.98 |
Technical Indicators
Market Signals| Indicator | OIA | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 20.40 | 35.96 |
| Support Level | N/A | $1.22 |
| Resistance Level | $6.23 | $1.76 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 2.50 | 5.56 |
Price Performance
Historical ComparisonAbout OIA Invesco Municipal Income Opportunities Trust
Invesco Municipal Income Opportunities Trust is a closed-end management investment company. The Trust's investment objective is to provide a high level of current income which is exempt from federal income tax.
About CDXS Codexis Inc.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.